ArticleInfectious diseases and therapy2026
Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study).
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionExtensive real-world data in people with HIV (PWH) switching from non-nucleoside reverse transcriptase inhibitors (NNRTIs), in particular from rilpivirine (RPV)-based regimens to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), are lacking.
methodsThis is a single-center retrospective study. Inclusion criteria were PWH aged ≥ 18 years, virologically suppressed on NNRTI triple antiretroviral regimens. The primary endpoint was the proportion of PWH with HIV-RNA < 50 cp/mL at 12 months from time of switch to B/F/TAF.
resultsOverall, 214 PWH were included, of whom 105 (49.1%) were switching from RPV/FTC/TAF. After 12 months, the proportion of PWH with HIV-RNA < 50 copies/mL was 82.7% (95% confidence interval, CI, 77.1-87.2) at intention-to-treat (ITT) and 95.7% (95% CI 91.7-97.8) at missing=excluded (M=E) analysis. In the group switching from RPV/FTC/TAF, the proportion of PWH with HIV-RNA < 50 copies/mL at 12 months was 74.3% (95% CI 65.2-81.7) at ITT and 95.1% (95% CI 88.1-98.1) at M=E analysis. Two PWH (0.93%, 95% CI 0.26-3.34) experienced virological failure after switching to B/F/TAF, with no resistance mutations detected. Six treatment discontinuations were observed (2.8%, 95% CI 1.3-5.6). A decrease in low-density lipoprotein (LDL) cholesterol was documented when switching from RPV/FTC/TAF to B/F/TAF.
conclusionSwitching to B/F/TAF from NNRTI-based regimens, particularly if RPV-based, showed high virological effectiveness and rare treatment discontinuations. No resistance mutations were detected at failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.